Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business News In Brief

Executive Summary

Sandoz names DeGolyer head of U.S. business: Sandoz appointed Don DeGolyer President of its U.S. business unit, replacing Christine Mundkur who is leaving to pursue other opportunities, the drug maker announced March 8. Mundkur served a short role at the company after leaving her position as chief executive of Barr to shape up Sandoz's U.S. operation and grow the generics business in early 2009 (1"The Pink Sheet," Feb. 16, 2009). DeGolyer most recently held the position of senior VP and head of U.S. Commercial Operations for Sandoz US. At the same time, Sandoz also appoints Richard Tremonte VP of U.S. Retail Sales and Marketing, from his post as senior director of marketing for Sandoz U.S., which he held after joining the company in 2007

You may also be interested in...



King Aims To File New Acurox NDA In Early 2011

King Pharmaceuticals expects to file a new drug application in early 2011 for its pain drug Acurox, excluding niacin as a potential abuse deterrent, execs told investors during a first quarter earnings call May 5

King Aims To File New Acurox NDA In Early 2011

King Pharmaceuticals expects to file a new drug application in early 2011 for its pain drug Acurox, excluding niacin as a potential abuse deterrent, execs told investors during a first quarter earnings call May 5

People In The News: Tracking The Latest Industry Personnel Moves

Presidents and CEOs

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel